Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.

@article{Ochi2011NovelAT,
  title={Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.},
  author={T. Ochi and Hiroshi Fujiwara and Sachiko Okamoto and Jun Yan An and Kozo Nagai and Toshiaki Shirakata and Junichi Mineno and Kiyotaka Kuzushima and Hiroshi Shiku and Masaki Yasukawa},
  journal={Blood},
  year={2011},
  volume={118 6},
  pages={1495-503}
}
Adoptive T-cell therapy for malignancies using redirected T cells genetically engineered by tumor antigen-specific T-cell receptor (TCR) gene transfer is associated with mispairing between introduced and endogenous TCR chains with unknown specificity. Therefore, deterioration of antitumor reactivity and serious autoimmune reactivity are major concerns. To address this problem, we have recently established a novel retroviral vector system encoding siRNAs for endogenous TCR genes (siTCR vector… CONTINUE READING